ライフサイエンスコーパス: prostaglandin E1

1 served upon stimulation of HEK293 cells with prostaglandin E1.

2 onophosphate (cAMP)-dependent secretagogues, prostaglandin E1 (1 mumol/L), forskolin (1 mumol/L), and

3 However, the plasma concentrations of prostaglandin E1 + 2, tumor necrosis factor-alpha, IL-6,

4 not significantly different in the liposomal prostaglandin E1 (40%) or placebo-treated (37%) groups.

5 ing stimulated platelets with the inhibitory prostaglandin E1, a cyclic RGD peptide, the monoclonal a

6 patients with ARDS, treatment with liposomal prostaglandin E1 accelerated improvement in indexes of o

7 Addition of forskolin or prostaglandin E1, agents known to elevate platelet cAMP

8 lation, 16.9 in patients receiving liposomal prostaglandin E1 and 19.6 in those administered placebo;

9 ntially inhibited by the platelet inhibitors prostaglandin E1 and theophylline, these inhibitors had

10 MRP4 substrates, the prostaglandins E1 and E2, stimulate ATP hydrolysis 2- to

11 Epinephrine, prostaglandin E1, and forskolin at maximum concentration

12 d in 69% of the patients receiving liposomal prostaglandin E1 compared with 33% of the placebo group,

13 data indicate that AS-013, a new prodrug of prostaglandin E1, could provide an effective and accepta

14 ndin E2 (PGE2), TxB2, and 6-keto PGF1 alpha; prostaglandins E1, D2, and F2 alpha and leukotrienes B4

15 nosine monophosphate (cAMP) generation after prostaglandin E1 exposure.

16 ratio >300 mm Hg: 9.8 days in the liposomal prostaglandin E1 group and 13.7 days in patients receivi

17 uation of ventilation, 10.3 in the liposomal prostaglandin E1 group and 16.3 days in patients receivi

18 mortality, 57 of 176 (32%) in the liposomal prostaglandin E1 group and 50 of 170 (29%) in patients r

19 continuation of ventilation in the liposomal prostaglandin E1 group compared with the placebo group (

20 Clinical trials of the potent vasodilator prostaglandin E1 have been disappointing.

21 clinical trial of AS-0:3, a novel prodrug of prostaglandin E1 incorporated into lipid microspheres th

22 timulated phosphoprotein phosphorylation and prostaglandin E1-induced increase in cyclic adenosine mo

23 We evaluated a system by which alprostadil (prostaglandin E1) is delivered transurethrally to treat

24 tify risk factors; 4) routine use of BAS and prostaglandin E1 may not be indicated in all cases; 5) e

25 l dose (i.e., > 45.9 microg/kg) of liposomal prostaglandin E1 (median number of days to discontinuati

26 was similar among patients in the liposomal prostaglandin E1 (n = 177) and the placebo (n = 171) tre

27 CD also reverses the inhibitory effects of prostaglandin E1 on vWF binding to GPIb-IX.

28 d in a 1:1 ratio to receive either liposomal prostaglandin E1 or placebo.

29 monophosphorothioate, Sp-isomer (Sp-cAMPS), prostaglandin E1, or the adenosine A2A receptor is suffi

30 prostaglandin E2 (PGE2) (P<0.01), 400% more prostaglandin E1 (PGE1) (P<0.01), and 250% more cAMP (P<

31 Using a connectivity map, we identified prostaglandin E1 (PGE1) as a small molecule that partly

32 Prostaglandin E1 (PGE1) has been used after orthotopic l

33 Prostaglandin E1 (PGE1) is often added to the donor pulm

34 Prostaglandin E1 (PGE1) prevents 4N1K-dependent aggregat

35 synthetic bicyclic fatty acid derivative of prostaglandin E1 (PGE1) used for chronic constipation.

36 Prostaglandin E1 (PGE1)-mediated inhibition of thrombin-

37 imulated (in response to isoproterenol), and prostaglandin E1 (PGE1)-stimulated lymphocyte adenylyl c

38 Prostaglandin E1 stimulated higher PKA activity in the c

39 30 min resulted in a significant increase in prostaglandin E1-stimulated cAMP accumulation in cells e

40 Cholesterol depletion abolished prostaglandin E1-stimulated CNGA2 channel activity in in

41 icant attenuation of isoproterenol-, but not prostaglandin E1-, stimulated adenylylcyclase activity.

42 linolenic acid diet released 35% or 24% more prostaglandin E1 than macrophages from rats given either

43 surgical timing, balloon atrial septostomy, prostaglandin E1 therapy, intraoperative techniques, ima

44 a (occurring in 52% and 24% of the liposomal prostaglandin E1-treated patients, respectively, and 17%

45 Scatchard analysis of the binding of [3H]prostaglandin E1, used as a prostacyclin receptor probe,

46 In contrast, treatment with liposomal prostaglandin E1 was associated with a significantly sho

47 CYP4A4-catalyzed omega-hydroxylation of prostaglandin E1 was supported by WT CYPOR but not by ei